The legacy of Viagra, and its parent company copyright, presents a intriguing case study for investors. Initially a blockbuster drug, yielding billions in income, its intellectual property lapse created a deluge of generic competition , significantly diminishing its dominance. While some firms may seek to capitalize on similar conditions , the curr